Cholesterol efflux mediators in homozygous familial hypercholesterolemia patients on low-density lipoprotein apheresis

被引:18
|
作者
Nenseter, Marit S. [1 ,2 ]
Narverud, Ingunn [1 ,3 ,4 ]
Graesdal, Asgeir [5 ]
Bogsrud, Martin P. [1 ,6 ]
Aukrust, Pal [2 ,7 ,8 ]
Retterstol, Kjetil [1 ]
Ose, Leiv [1 ]
Halvorsen, Bente [2 ,8 ]
Holven, Kirsten B. [3 ]
机构
[1] Univ Oslo, Rikshosp, Oslo Univ Hosp, Lipid Clin, N-0027 Oslo, Norway
[2] Univ Oslo, Rikshosp, Oslo Univ Hosp, Internal Med Res Inst, N-0027 Oslo, Norway
[3] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Oslo, Norway
[4] Oslo & Akershus Univ, Coll Appl Sci, Dept Hlth Nutr & Management, Fac Hlth Sci, Oslo, Norway
[5] Vestfold Ctr Internal Med, Sandefjord, Norway
[6] Alesund More & Romsdal Hlth Trust, Dept Internal Med, Alesund, Norway
[7] Univ Oslo, Rikshosp, Oslo Univ Hosp, Sect Clin Immunol & Infect Dis, N-0027 Oslo, Norway
[8] Univ Oslo, Fac Med, Oslo, Norway
关键词
ABCA1; ABCG1; Cholesterol efflux; Familial hypercholesterolemia; LDL apheresis; SR-BI; LDL-APHERESIS; TRANSPORT PATHWAY; ATHEROSCLEROSIS; CAPACITY; BINDING;
D O I
10.1016/j.jacl.2012.08.001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
BACKGROUND: Homozygous familial hypercholesterolemia (FH) is a rare disorder that may affect 1 person per million. Early initiation of aggressive cholesterol-lowering therapy is essential to prevent premature coronary heart disease. Selective removal of low-density lipoprotein (LDL) by LDL apheresis is a reliable method of treatment. METHODS AND RESULTS: Cholsterol efflux mediators of homozygous FH patients on weekly LDL apheresis were compared with those of age- and sex-matched heterozygous FH patients receiving oral medication only and with healthy control subjects. The data show that (1) compared with healthy controls, homozygous FH patients have significantly lower plasma levels of high-density lipoprotein cholesterol and apoA-I and significantly lower cholesterol-acceptor capacity of serum to promote cholesterol efflux from cholesterol-loaded THP-1 cells, combined with significantly lower peripheral blood mononuclear cell gene expression levels of ATP-binding cassette (ABC) transporter G1 and borderline-significantly lower levels of ABCA1 and scavenger receptor class B type I (SR-BI); and (2) compared with pre-LDL apheresis (a day before treatment), postapheresis (15 days later; on the day after the weekly treatment) levels of HDL cholesterol and apoA-I were significantly reduced, with no significant effect on cholesterol-acceptor capacity of serum or on peripheral blood mononuclear cell gene expression levels of the cellular transporters, except for a borderline-significant reduction in ABCA1 mRNA levels. CONCLUSIONS: The data showing decreased levels of cholesterol efflux mediators in plasma and cells may suggest that the overall cholesterol efflux capacity is impaired in homozygous FH patients. However, LDL apheresis may maintain cholesterol efflux capacity, despite a lowering levels of highdensity lipoprotein cholesterol and apoA-I. (C) 2013 National Lipid Association. All rights reserved.
引用
收藏
页码:109 / 116
页数:8
相关论文
共 50 条
  • [31] Low-density lipoprotein receptor genotypes modify the sera metabolome of patients with homozygous familial hypercholesterolemia
    Du, Zhiyong
    Li, Fan
    Li, Linyi
    Wang, Yu
    Li, Jianping
    Yang, Ya
    Jiang, Long
    Wang, Luya
    Qin, Yanwen
    ISCIENCE, 2022, 25 (11)
  • [32] MEMBRANE LOW-DENSITY-LIPOPROTEIN APHERESIS IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    VONBAEYER, H
    SCHWERDTFEGER, R
    KOCHINKE, F
    SCHWANER, I
    ARTIFICIAL ORGANS, 1986, 10 (01) : 71 - 71
  • [33] Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia
    Nomura, Akihiro
    Sato, Takehiro
    Tada, Hayato
    Kannon, Takayuki
    Hosomichi, Kazuyoshi
    Tsujiguchi, Hiromasa
    Nakamura, Hiroyuki
    Takamura, Masayuki
    Tajima, Atsushi
    Kawashiri, Masa-aki
    JOURNAL OF HUMAN GENETICS, 2021, 66 (11) : 1079 - 1087
  • [34] LOW-DENSITY LIPOPROTEIN (LDL) RECEPTOR ACTIVITY IN HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (FH)
    SEMENKOVICH, CF
    OSTLUND, RE
    OSA, SR
    LEVY, RA
    CLINICAL RESEARCH, 1981, 29 (02): : A422 - A422
  • [35] Polygenic risk scores for low-density lipoprotein cholesterol and familial hypercholesterolemia
    Akihiro Nomura
    Takehiro Sato
    Hayato Tada
    Takayuki Kannon
    Kazuyoshi Hosomichi
    Hiromasa Tsujiguchi
    Hiroyuki Nakamura
    Masayuki Takamura
    Atsushi Tajima
    Masa-aki Kawashiri
    Journal of Human Genetics, 2021, 66 : 1079 - 1087
  • [36] LOW-DENSITY LIPOPROTEIN (LDL) CHOLESTEROL IMMUNOPHERESIS IN TREATING 3 PATIENTS WITH FAMILIAL HYPERCHOLESTEROLEMIA
    KUKHARCHUK, VV
    KONOVALOV, GA
    KURDANOV, KA
    VEDERNIKOV, AY
    POKROVSKY, SN
    ALFERYEV, AM
    KHASHIMOV, KA
    ARTIFICIAL ORGANS, 1988, 12 (03) : 277 - 277
  • [37] 3 DIFFERENT SCHEDULES OF LOW-DENSITY-LIPOPROTEIN APHERESIS COMPARED WITH PLASMAPHERESIS IN PATIENTS WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
    BERGER, GM
    FIRTH, JC
    JACOBS, P
    WOOD, L
    MARAIS, AD
    HORAK, A
    AMERICAN JOURNAL OF MEDICINE, 1990, 88 (02): : 94 - 100
  • [38] TREATMENT OF CHILDREN WITH HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA - SAFETY AND EFFICACY OF LOW-DENSITY-LIPOPROTEIN APHERESIS
    UAUY, R
    ZWIENER, RJ
    PHILLIPS, MJ
    PETRUSKA, ML
    BILHEIMER, DW
    JOURNAL OF PEDIATRICS, 1992, 120 (06): : 892 - 898
  • [39] Lomitapide and Mipomersen Two First-in-Class Drugs for Reducing Low-Density Lipoprotein Cholesterol in Patients With Homozygous Familial Hypercholesterolemia
    Rader, Daniel J.
    Kastelein, John J. P.
    CIRCULATION, 2014, 129 (09) : 1022 - 1032
  • [40] The effect of growth hormone on low-density lipoprotein cholesterol and lipoprotein(a) levels in familial hypercholesterolemia
    Tonstad, S
    Sundt, E
    Ose, L
    Hagve, TA
    Fruchart, JC
    Bard, JM
    Eden, S
    METABOLISM-CLINICAL AND EXPERIMENTAL, 1996, 45 (11): : 1415 - 1421